EFFECTS OF HYDROXYCHLOROQUINE PLUS FAVIPIRAVIR TREATMENT ON THE CLINICAL COURSE AND BIOMARKERS IN HOSPITALIZED COVID-19 PATIENTS WITH PNEUMONIA

Basit Öğe Kaydı
dc.authoridKasapoglu, Umut Sabri/0000-0003-2869-9872|Ekici gok, Zarife/0000-0002-9250-9618|TETIK, Bora/0000-0001-7696-7785
dc.contributor.authorDelen, Leman Acun
dc.contributor.authorGok, Abdullah
dc.contributor.authorKasapoglu, Umut Sabri
dc.contributor.authorCagasar, Ozlem
dc.contributor.authorGok, Zarife
dc.contributor.authorBerber, Nurcan
dc.contributor.authorDerya, Serdar
dc.date.accessioned2025-10-24T18:09:38Z
dc.date.available2025-10-24T18:09:38Z
dc.date.issued2022
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractBackground: The novel coronavirus disease 2019 (COVID-19) has a broad spectrum of clin-ical manifestations, the most common serious clinical manifestation of the coronavirus infection being pneumo-nia. Unfortunately, the optimal treatment approach is still uncertain. However, many studies have been conducted on the effectiveness of several medications in the treatment of COVID-19 infection. The aim of this study was to evaluate the effectiveness of the hydroxychloroquine (HCQ) + favipiravir (FAV) treatment regimen and HCQ alone by comparing the patient's clinical response and laboratory results on the fifth day of treatment in patients hospitalized due to COVID-19 infection.Patients and methods: This retrospective cohort study was conducted in Malatya Training and Research Hospital between March 2020 and July 2020. The study included 69 patients with confirmed COVID-19 with pneumonia. The patients were divided into 2 groups, those receiving HCQ alone and those receiving the HCQ + FAV combination.Results: A total of 69 patients were included in the study, and the mean age was 60.09 +/- 15.56 years. A statisti-cally significant decrease was observed in C-reactive protein (CRP) levels, at the end of the fifth day, in patients who received HCQ + FAV treatment (p=0.002), whereas there was no decrease in CRP levels in patients who received HCQ treatment alone. In addition, an increase in lymphocyte count and a better fever response was observed at the end of the fifth day in patients who received HCQ + FAV (p=0.008). However, there was no statistical difference between both treatment regimens in terms of hospital stay and treatment results (p=0.008, p=0.744, p=0.517).Conclusion: Although the combination of HCQ + FAV treatment was observed to be effective on CRP levels and fever response in patients with COVID-19 pneumonia, there was no difference in terms of hospital stay and discharge.
dc.identifier.doi10.20471/acc.2022.61.03.05
dc.identifier.endpage411
dc.identifier.issn0353-9466
dc.identifier.issn1333-9451
dc.identifier.issue3
dc.identifier.pmid37492367
dc.identifier.startpage403
dc.identifier.urihttps://doi.org/10.20471/acc.2022.61.03.05
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3754
dc.identifier.volume61
dc.identifier.wosWOS:000958104900005
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSestre Milosrdnice Univ Hospital
dc.relation.ispartofActa Clinica Croatica
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20251023
dc.subjectFavipiravir; hydroxychloroquine; COVID-19; SARS-COV-2; pneumonia
dc.titleEFFECTS OF HYDROXYCHLOROQUINE PLUS FAVIPIRAVIR TREATMENT ON THE CLINICAL COURSE AND BIOMARKERS IN HOSPITALIZED COVID-19 PATIENTS WITH PNEUMONIA
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu